# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and lowers the price target from $...
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval
The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for ...
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...
The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was...